SOURCE: ImmuCell Corporation

March 12, 2008 08:30 ET

ImmuCell Announces Cross-License With Anadis

PORTLAND, ME--(Marketwire - March 12, 2008) - ImmuCell Corporation (NASDAQ: ICCC) today announced that it had entered into a cross-license of technology with Anadis Limited (ASX: ANX) of Australia.

ImmuCell granted Anadis an exclusive, worldwide license to the human and environmental applications of its milk antibody technology. Under this agreement, ImmuCell is not obligated to fund further product development and is entitled to receive a royalty on any sales achieved by Anadis utilizing the technology.

In return, ImmuCell was granted a license to the production technology and capabilities of Anadis in Australia. ImmuCell is obligated to pay Anadis a royalty on any sales of First Defense® manufactured in collaboration with Anadis in Australia.

Anadis is an Australian-based biotechnology company focused on milk derived polyclonal antibodies and other milk-derived bioactives for human and environmental health applications.

ImmuCell Corporation is a biotechnology company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries. Press releases and other information about the Company are available at

Contact Information

  • Contact:
    Michael F. Brigham
    President and Chief Executive Officer
    (207) 878-2770 Ext. 3106